• 1
    World_Health_Organization. Obesity and overweight – Fact Sheet N°311. [WWW document]. URL (accessed 1 September 2010). 2006.
  • 2
    International_Diabetes_Federation. Diabetes Atlas – Prevalence and Projections. [WWW document]. URL (accessed 1 September 2010). 2008.
  • 3
    Astrup A, Finer N. Redefining type 2 diabetes: ‘diabesity’ or ‘obesity dependent diabetes mellitus’? Obes Rev 2000; 1: 5759.
  • 4
    Global_Alliance_for_the_Prevention_of_Obesity_and_Related_Chronic_Disease. [WWW document]. URL (accessed 1 September 2010). 2008.
  • 5
    Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 21292140.
  • 6
    Puterbaugh JS. The emperor's tailors: the failure of the medical weight loss paradigm and its causal role in the obesity of America. Diabetes Obes Metab 2009; 11: 557570.
  • 7
    Ashrafian H, Bueter M, Ahmed K, Suliman A, Bloom SR, Darzi A, Athanasiou T. Metabolic surgery: an evolution through bariatric animal models. Obes Rev 2009 Dec 29. [Epub ahead of print] PubMed PMID: 20051020.
  • 8
    Ashrafian H, le Roux CW, Darzi A, Athanasiou T. Effects of bariatric surgery on cardiovascular function. Circulation 2008; 118: 20912102.
  • 9
    Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741752.
  • 10
    Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 26832693.
  • 11
    Ashrafian H, le Roux CW. Metabolic surgery and gut hormones – a review of bariatric entero-humoral modulation. Physiol Behav 2009; 97: 620631.
  • 12
    Ashrafian H, Darzi A, Athanasiou T. Autobionics: a new paradigm in regenerative medicine and surgery. Regen Med 2010; 5: 279288.
  • 13
    Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009; 19: 16051611.
  • 14
    Cummings DE. Gastric bypass and nesidioblastosis – too much of a good thing for islets? N Engl J Med 2005; 353: 300302.
  • 15
    Mason EE, Ito C. Gastric bypass in obesity. Surg Clin North Am 1967; 47: 13451351.
  • 16
    Suter M, Calmes JM, Paroz A, Romy S, Giusti V. Results of Roux-en-Y gastric bypass in morbidly obese vs superobese patients: similar body weight loss, correction of comorbidities, and improvement of quality of life. Arch Surg 2009; 144: 312318.
  • 17
    Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, Pories W, Courcoulas A, McCloskey C, Mitchell J, Patterson E, Pomp A, Staten MA, Yanovski SZ, Thirlby R, Wolfe B. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361: 445454.
  • 18
    Robinson MK. Surgical treatment of obesity – weighing the facts. N Engl J Med 2009; 361: 520521.
  • 19
    Gracia JA, Martinez M, Elia M, Aguilella V, Royo P, Jimenez A, Bielsa MA, Arribas D. Obesity surgery results depending on technique performed: long-term outcome. Obes Surg 2009; 19: 432438.
  • 20
    Van Hee RH. Biliopancreatic diversion in the surgical treatment of morbid obesity. World J Surg 2004; 28: 435444.
  • 21
    Tice JA, Karliner L, Walsh J, Petersen AJ, Feldman MD. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med 2008; 121: 885893.
  • 22
    Carrasco F, Papapietro K, Csendes A, Salazar G, Echenique C, Lisboa C, Diaz E, Rojas J. Changes in resting energy expenditure and body composition after weight loss following Roux-en-Y gastric bypass. Obes Surg 2007; 17: 608616.
  • 23
    Patriti A, Facchiano E, Sanna A, Gulla N, Donini A. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 2004; 14: 840848.
  • 24
    Bueter M, Ahmed A, Ashrafian H, le Roux CW. Bariatric surgery and hypertension. Surg Obes Relat Dis 2009; 5: 615620.
  • 25
    Flickinger EG, Pories WJ, Meelheim HD, Sinar DR, Blose IL, Thomas FT. The Greenville gastric bypass. Progress report at 3 years. Ann Surg 1984; 199: 555562.
  • 26
    Pories WJ, Caro JF, Flickinger EG, Meelheim HD, Swanson MS. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 1987; 206: 316323.
  • 27
    Halverson JD, Kramer J, Cave A, Permutt A, Santiago J. Altered glucose tolerance, insulin response, and insulin sensitivity after massive weight reduction subsequent to gastric bypass. Surgery 1982; 92: 235240.
  • 28
    Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339350. discussion 350–352.
  • 29
    MacDonald KG Jr, Long SD, Swanson MS, Brown BM, Morris P, Dohm GL, Pories WJ. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997; 1: 213220. discussion 220.
  • 30
    Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003; 238: 467484. discussion 484–485.
  • 31
    Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003; 237: 751756. discussion 757–758.
  • 32
    Torquati A, Lutfi R, Abumrad N, Richards WO. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg 2005; 9: 11121116. discussion 1117–1118.
  • 33
    Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 17241737.
  • 34
    Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248256. e5.
  • 35
    Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008; 31: 8186.
  • 36
    Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7: 477484.
  • 37
    Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg 2005; 15: 474481.
  • 38
    Lee WJ, Lee YC, Ser KH, Chen JC, Chen SC. Improvement of insulin resistance after obesity surgery: a comparison of gastric banding and bypass procedures. Obes Surg 2008; 18: 11191125.
  • 39
    Muscelli E, Mingrone G, Camastra S, Manco M, Pereira JA, Pareja JC, Ferrannini E. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med 2005; 118: 5157.
  • 40
    Lin E, Davis SS, Srinivasan J, Sweeney JF, Ziegler TR, Phillips L, Gletsu-Miller N. Dual mechanism for type-2 diabetes resolution after Roux-en-Y gastric bypass. Am Surg 2009; 75: 498502. discussion 502–503.
  • 41
    Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353: 249254.
  • 42
    Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 Jan 25; (1): CD004096. Review. PubMed PMID: 15674929.
  • 43
    Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004; 164: 13951404.
  • 44
    Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 16771686.
  • 45
    Lean ME, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228233.
  • 46
    Meirelles K, Ahmed T, Culnan DM, Lynch CJ, Lang CH, Cooney RN. Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg 2009; 249: 277285.
  • 47
    Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Kovack B, Bawa B, Koshy N, Lee H, Yapp K, Olivan B. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 24792485.
  • 48
    le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108114.
  • 49
    Gumbs AA, Modlin IM, Ballantyne GH. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg 2005; 15: 462473.
  • 50
    Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007; 3: 597601.
  • 51
    Lee WJ, Lee YC, Chen JC, Ser KH, Chen SC, Lin CM. A randomized trial comparing laparoscopic sleeve gastrectomy versus gastric bypass for the treatment of type 2 diabetes mellitus: Preliminary report. Surg Obes Relat Dis 2009; 4: 290.
  • 52
    Lee WJ, Wang W, Lee YC, Huang MT, Ser KH, Chen JC. Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI >35 and <35 kg/m2. J Gastrointest Surg 2008; 12: 945952.
  • 53
    Cohen R, Pinheiro JS, Correa JL, Schiavon CA. Laparoscopic Roux-en-Y gastric bypass for BMI < 35 kg/m(2): a tailored approach. Surg Obes Relat Dis 2006; 2: 401404. discussion 404.
  • 54
    Ramos A, Galvao Neto MP, Galvao M, Souza Y, Murakami AH, Carlo A, Canseco EG, Campos JM, Escalona A. V-008: Metabolic Laparoscopic Roux-En-Y Gastric Bypass: Technical Highlights and Initial Results. International Federation for the Surgery of Obesity and metabolic disorders. XIV World Congress: Palais des Congres (Porte Maillot) – Paris, France August 26–29, 2009. Obes Surg 2009; 19: 9531076.
  • 55
    Rubino F, Kaplan LM, Schauer PR, Cummings DE. The Diabetes Surgery Summit Consensus Conference: Recommendations for the Evaluation and Use of Gastrointestinal Surgery to Treat Type 2 Diabetes Mellitus. Ann Surg 2010; 251: 399405.
  • 56
    Schauer PR. The Expert Weighs In: Swedish Obesity Subjects: Interviewed with Dr. Lars Sjöström, M.D., Ph.D., Professor and Swedish Obesity Subjects (SOS) secretariat, Institution of Internal Medicine, Gothenburg. Sweden Obes Manag 2009; 5: 101107.
  • 57
    Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in overweight white men aged 40–64 years. Am J Epidemiol 1999; 149: 491503.
  • 58
    Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 14991504.
  • 59
    Christou NV, Sampalis JS, Liberman M, Look D, Auger S, McLean AP, MacLean LD. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004; 240: 416423. discussion 423–424.
  • 60
    Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753761.
  • 61
    Hickey MS, Pories WJ, MacDonald KG, Jr, Cory KA, Dohm GL, Swanson MS, Israel RG, Barakat HA, Considine RV, Caro JF, Houmard JA. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg 1998; 227: 637643. discussion 643–644.
  • 62
    Pories WJ, Albrecht RJ. Etiology of type II diabetes mellitus: role of the foregut. World J Surg 2001; 25: 527531.
  • 63
    Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004; 239: 111.
  • 64
    Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006; 244: 741749.
  • 65
    Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 2000; 141: 111117.
  • 66
    Cohen RV, Schiavon CA, Pinheiro JS, Correa JL, Rubino F. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surg Obes Relat Dis 2007; 3: 195197.
  • 67
    Ramos AC, Galvao Neto MP, de Souza YM, Galvao M, Murakami AH, Silva AC, Canseco EG, Santamaria R, Zambrano TA. Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI < 30 kg/m2 (LBMI). Obes Surg 2009; 19: 307312.
  • 68
    Swarbrick MM, Stanhope KL, Austrheim-Smith IT, Van Loan MD, Ali MR, Wolfe BM, Havel PJ. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia 2008; 51: 19011911.
  • 69
    Halperin F, Patti ME, Goldfine AB. Glucagon treatment for post-gastric bypass hypoglycemia. Obesity (Silver Spring) 2010 Sep; 18(9): 18581860. Epub 2010 Feb 18. PubMed PMID: 20168313.
  • 70
    De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, Bengtsson M, Braha O, Braun M, Ramracheya R, Amisten S, Habib AM, Moritoh Y, Zhang E, Reimann F, Rosengren AH, Shibasaki T, Gribble F, Renstrom E, Seino S, Eliasson L, Rorsman P. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab 2010; 11: 543553.
  • 71
    Aguirre V, Stylopoulos N, Grinbaum R, Kaplan LM. An endoluminal sleeve induces substantial weight loss and normalizes glucose homeostasis in rats with diet-induced obesity. Obesity (Silver Spring) 2008; 16: 25852592.
  • 72
    Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis 2008; 4: 5559.
  • 73
    Tarnoff M, Shikora S, Lembo A, Gersin K. Chronic in-vivo experience with an endoscopically delivered and retrieved duodenal-jejunal bypass sleeve in a porcine model. Surg Endosc 2008; 22: 10231028.
  • 74
    Schouten R, Rijs CS, Bouvy ND, Hameeteman W, Koek GH, Janssen IM, Greve JW. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg 2010; 251: 236243.
  • 75
    Mithieux G. A novel function of intestinal gluconeogenesis: central signaling in glucose and energy homeostasis. Nutrition 2009; 25: 881884.
  • 76
    Troy S, Soty M, Ribeiro L, Laval L, Migrenne S, Fioramonti X, Pillot B, Fauveau V, Aubert R, Viollet B, Foretz M, Leclerc J, Duchampt A, Zitoun C, Thorens B, Magnan C, Mithieux G, Andreelli F. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab 2008; 8: 201211.
  • 77
    Burcelin R, Dolci W, Thorens B. Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice. Diabetes 2000; 49: 16431648.
  • 78
    Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol 2003; 81: 10051012.
  • 79
    de Paula AL, Macedo AL, Prudente AS, Queiroz L, Schraibman V, Pinus J. Laparoscopic sleeve gastrectomy with ileal interposition (‘neuroendocrine brake’) – pilot study of a new operation. Surg Obes Relat Dis 2006; 2: 464467.
  • 80
    DePaula AL, Macedo AL, Mota BR, Schraibman V. Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21–29. Surg Endosc 2009; 23: 13131320.
  • 81
    DePaula AL, Macedo AL, Rassi N, Machado CA, Schraibman V, Silva LQ, Halpern A. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc 2008; 22: 706716.
  • 82
    DePaula AL, Macedo AL, Rassi N, Vencio S, Machado CA, Mota BR, Silva LQ, Halpern A, Schraibman V. Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. Surg Endosc 2008; 22: 26702678.
  • 83
    DePaula AL, Macedo AL, Schraibman V, Mota BR, Vencio S. Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20–34. Surg Endosc 2009; 23: 17241732.
  • 84
    Patriti A, Aisa MC, Annetti C, Sidoni A, Galli F, Ferri I, Gulla N, Donini A. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell number. Surgery 2007; 142: 7485.
  • 85
    De Block CE, Van Gaal LF. GLP-1 receptor agonists for type 2 diabetes. Lancet 2009; 374: 46.
  • 86
    Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract 2006; 60: 16541661.
  • 87
    de Campos Martins MV, Peixoto AA, Schanaider A, Esposito CC, Aratanha CB. Glucose tolerance in the proximal versus the distal small bowel in Wistar rats. Obes Surg 2009; 19: 202206.
  • 88
    Sun Y, Asnicar M, Smith RG. Central and peripheral roles of ghrelin on glucose homeostasis. Neuroendocrinology 2007; 86: 215228.
  • 89
    Dezaki K, Sone H, Yada T. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 2008; 118: 239249.
  • 90
    Allen FM. Current judgments on metabolic control and complications in diabetes. N Engl J Med 1953; 248: 133136.
  • 91
    Joslin EP. Diabetes for the diabetics; ninth Banting Memorial Lecture of the British Diabetic Association. Diabetes 1956; 5: 137146.
  • 92
    Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985; 61: 917925.
  • 93
    Aoki TT. Metabolic adaptations to starvation, semistarvation, and carbohydrate restriction. Prog Clin Biol Res 1981; 67: 161177.
  • 94
    Graham GG. Starvation in the modern world. N Engl J Med 1993; 328: 10581061.
  • 95
    Wang Y, Liu J. Combination of Bypassing Stomach and Vagus Dissection in High-Fat Diet-Induced Obese Rats-A Long-Term Investigation. Obes Surg 2009.
  • 96
    Bergman RN, Miller RE. Direct enhancement of insulin secretion by vagal stimulation of the isolated pancreas. Am J Physiol 1973; 225: 481486.
  • 97
    Mikhailidis DP, Foo Y, Ramdial L, Kirk RM, Rosalki SB, Dandona P. Pancreatic exocrine function after truncal and highly selective vagotomy. J Clin Pathol 1981; 34: 963964.
  • 98
    Herath CB, Reynolds GW, MacKenzie DD, Davis SR, Harris PM. Vagotomy suppresses cephalic phase insulin release in sheep. Exp Physiol 1999; 84: 559569.
  • 99
    Williams DL, Grill HJ, Cummings DE, Kaplan JM. Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 2003; 144: 51845187.
  • 100
    Wang PY, Caspi L, Lam CK, Chari M, Li X, Light PE, Gutierrez-Juarez R, Ang M, Schwartz GJ, Lam TK. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 2008; 452: 10121016.
  • 101
    Burge JC, Schaumburg JZ, Choban PS, DiSilvestro RA, Flancbaum L. Changes in patients' taste acuity after Roux-en-Y gastric bypass for clinically severe obesity. J Am Diet Assoc 1995; 95: 666670.
  • 102
    Olbers T, Bjorkman S, Lindroos A, Maleckas A, Lonn L, Sjostrom L, Lonroth H. Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg 2006; 244: 715722.
  • 103
    Scruggs DM, Buffington C, Cowan GS Jr. Taste Acuity of the Morbidly Obese before and after Gastric Bypass Surgery. Obes Surg 1994; 4: 2428.
  • 104
    Vincent RP, Ashrafian H, le Roux CW. Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 268277.
  • 105
    Tonosaki K, Hori Y, Shimizu Y. Relationships between insulin release and taste. Biomed Res 2007; 28: 7983.
  • 106
    Grudell AB, Camilleri M. The role of peptide YY in integrative gut physiology and potential role in obesity. Curr Opin Endocrinol Diabetes Obes 2007; 14: 5257.
  • 107
    Liu W, Yue W, Wu R. Effects of diabetes on expression of glial fibrillary acidic protein and neurotrophins in rat colon. Auton Neurosci 2010; 154: 7983.
  • 108
    Guijarro A, Suzuki S, Chen C, Kirchner H, Middleton FA, Nadtochiy S, Brookes PS, Niijima A, Inui A, Meguid MM. Characterization of weight loss and weight regain mechanisms after Roux-en-Y gastric bypass in rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1474R1489.
  • 109
    Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, Greig NH. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007; 203: 293301.
  • 110
    Jin HY, Liu WJ, Park JH, Baek HS, Park TS. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res 2009; 40: 536544.
  • 111
    Bharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, Zinsmeister AR, Low PA. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 2008; 295: R874R880.
  • 112
    Whitson BA, Leslie DB, Kellogg TA, Maddaus MA, Buchwald H, Billington CJ, Ikramuddin S. Adipokine response in diabetics and nondiabetics following the Roux-en-Y gastric bypass: a preliminary study. J Surg Res 2007; 142: 295300.
  • 113
    Ballantyne GH, Gumbs A, Modlin IM. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg 2005; 15: 692699.
  • 114
    Trakhtenbroit MA, Leichman JG, Algahim MF, Miller CC 3rd, Moody FG, Lux TR, Taegtmeyer H. Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery. Am J Med 2009; 122: 435442.
  • 115
    Kopp HP, Krzyzanowska K, Mohlig M, Spranger J, Pfeiffer AF, Schernthaner G. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (Lond) 2005; 29: 766771.
  • 116
    Uzun H, Zengin K, Taskin M, Aydin S, Simsek G, Dariyerli N. Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding. Obes Surg 2004; 14: 659665.
  • 117
    Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302: 179188.
  • 118
    Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin – a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264280.
  • 119
    Wilding JP. The importance of free fatty acids in the development of Type 2 diabetes. Diabet Med 2007; 24: 934945.
  • 120
    Taubes G. Insulin resistance. Prosperity's plague. Science 2009; 325: 256260.
  • 121
    Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord 2009; 7: 255258.
  • 122
    Forman BM, Lin M, Jones MR, Abby SL, Van Critters G. Colesevelam HCl affects gene expression in metabolic tissues in db/db mice. American Diabetes Association (ADA) 68th Scientific Sessions (San Francisco). 2008.
  • 123
    Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167177.
  • 124
    Cao R, Cronk ZX, Zha W, Sun L, Wang X, Fang Y, Studer E, Zhou H, Pandak WM, Dent P, Gil G, Hylemon PB. Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via G(alpha)i-protein-coupled receptors and the AKT pathway. J Lipid Res 2010 Aug; 51(8): 22342244. Epub 2010 Mar 20. PubMed PMID: 20305288; PubMed Central PMCID: PMC2903791.
  • 125
    Suzuki T, Oba K, Igari Y, Matsumura N, Watanabe K, Futami-Suda S, Yasuoka H, Ouchi M, Suzuki K, Kigawa Y, Nakano H. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7–36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007; 74: 338343.
  • 126
    Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J, Auwerx J, Goldfine AB. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009 Sep; 17(9): 16711677. Epub 2009 Apr 9. PubMed PMID: 19360006.
  • 127
    Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008; 14: 222231.
  • 128
    Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008; 454: 470477.
  • 129
    Duffaut C, Zakaroff-Girard A, Bourlier V, Decaunes P, Maumus M, Chiotasso P, Sengenès C, Lafontan M, Galitzky J, Bouloumié A. Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators. Arterioscler Thromb Vasc Biol 2009 Oct; 29(10): 16081614. Epub 2009 Jul 30. PubMed PMID: 19644053.
  • 130
    Vazquez LA, Pazos F, Berrazueta JR, Fernandez-Escalante C, Garcia-Unzueta MT, Freijanes J, Amado JA. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2005; 90: 316322.
  • 131
    Holdstock C, Lind L, Engstrom BE, Ohrvall M, Sundbom M, Larsson A, Karlsson FA. CRP reduction following gastric bypass surgery is most pronounced in insulin-sensitive subjects. Int J Obes (Lond) 2005; 29: 12751280.
  • 132
    Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, Schernthaner G. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 10421047.
  • 133
    Lindon JC, Nicholson JK. Analytical technologies for metabonomics and metabolomics, and multi-omic information recovery. Trends Analyt Chem 2008; 27: 194204.
  • 134
    Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature 2008; 455: 10541056.
  • 135
    Mutch DM, Fuhrmann JC, Rein D, Wiemer JC, Bouillot JL, Poitou C, Clement K. Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS ONE 2009; 4: e7905.
  • 136
    Flier JS, Mekalanos JJ. Gut check: testing a role for the intestinal microbiome in human obesity. Sci Transl Med 2009; 1: 6ps7.
  • 137
    Tsai F, Coyle WJ. The microbiome and obesity: is obesity linked to our gut flora? Curr Gastroenterol Rep 2009; 11: 307313.
  • 138
    Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 10221023.
  • 139
    Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 2009; 106: 23652370.
  • 140
    Rehfeld JF. A centenary of gastrointestinal endocrinology. Horm Metab Res 2004; 36: 735741.
  • 141
    Kirchner H, Gutierrez JA, Solenberg PJ, Pfluger PT, Czyzyk TA, Willency JA, Schurmann A, Joost HG, Jandacek RJ, Hale JE, Heiman ML, Tschop MH. GOAT links dietary lipids with the endocrine control of energy balance. Nat Med 2009; 15: 741745.
  • 142
    Gong J, Sun Z, Li P. CIDE proteins and metabolic disorders. Curr Opin Lipidol 2009; 20: 121126.
  • 143
    Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y, Endo M, Urano T, Zhu HJ, Tsukano H, Tazume H, Kaikita K, Miyashita K, Iwawaki T, Shimabukuro M, Sakaguchi K, Ito T, Nakagata N, Yamada T, Katagiri H, Kasuga M, Ando Y, Ogawa H, Mochizuki N, Itoh H, Suda T, Oike Y. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab 2009; 10: 178188.
  • 144
    Kellogg TA, Bantle JP, Leslie DB, Redmond JB, Slusarek B, Swan T, Buchwald H, Ikramuddin S. Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. Surg Obes Relat Dis 2008; 4: 492499.
  • 145
    Kapoor RR, James C, Hussain K. Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. Nat Clin Pract Endocrinol Metab 2009; 5: 101112.
  • 146
    Alvarez GC, Faria EN, Beck M, Girardon DT, Machado AC. Laparoscopic spleen-preserving distal pancreatectomy as treatment for nesidioblastosis after gastric bypass surgery. Obes Surg 2007; 17: 550552.
  • 147
    Kaczirek K, Niederle B. Nesidioblastosis: an old term and a new understanding. World J Surg 2004; 28: 12271230.
  • 148
    Kloppel G, Anlauf M, Raffel A, Perren A, Knoefel WT. Adult diffuse nesidioblastosis: genetically or environmentally induced? Hum Pathol 2008; 39: 38.
  • 149
    Meier JJ, Butler AE, Galasso R, Butler PC. Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care 2006; 29: 15541559.
  • 150
    Meier JJ, Nauck MA, Butler PC. Comment to: Patti ME, McMahon G, Mun EC et al. (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236–2240. Diabetologia 2006; 49: 607608. author reply 609–610.
  • 151
    Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009; 150: 25182525.
  • 152
    Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, Hanto DW, Callery M, Arky R, Nose V, Bonner-Weir S, Goldfine AB. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005; 48: 22362240.
  • 153
    Clancy TE, Moore FD Jr, Zinner MJ. Post-gastric bypass hyperinsulinism with nesidioblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia. J Gastrointest Surg 2006; 10: 11161119.
  • 154
    Abellan P, Camara R, Merino-Torres JF, Perez-Lazaro A, del Olmo MI, Ponce JL, Rayon JM, Pinon F. Severe hypoglycemia after gastric bypass surgery for morbid obesity. Diabetes Res Clin Pract 2008; 79: e7e9.
  • 155
    Z'Graggen K, Guweidhi A, Steffen R, Potoczna N, Biral R, Walther F, Komminoth P, Horber F. Severe recurrent hypoglycemia after gastric bypass surgery. Obes Surg 2008; 18: 981988.
  • 156
    Rumilla KM, Erickson LA, Service FJ, Vella A, Thompson GB, Grant CS, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis: histologic features and growth factor expression. Mod Pathol 2009; 22: 239245.
  • 157
    Goldfine AB, Mun EC, Devine E, Bernier R, Baz-Hecht M, Jones DB, Schneider BE, Holst JJ, Patti ME. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007; 92: 46784685.
  • 158
    Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003; 17: 161171.
  • 159
    Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ. Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 2008; 149: 13381349.
  • 160
    Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141: 46004605.
  • 161
    Duxbury MS, Waseem T, Ito H, Robinson MK, Zinner MJ, Ashley SW, Whang EE. Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness. Biochem Biophys Res Commun 2003; 309: 464468.
  • 162
    Nikolopoulos D, Theocharis S, Kouraklis G. Ghrelin's role on gastrointestinal tract cancer. Surg Oncol 2010 Mar; 19(1): e2e10. Epub 2009 Mar 28. PubMed PMID: 19328680.
  • 163
    Volante M, Allia E, Gugliotta P, Funaro A, Broglio F, Deghenghi R, Muccioli G, Chigo E, Papotti M. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab 2002; 87: 13001308.
  • 164
    Scavini M, Pontiroli AE, Folli F. Asymptomatic hyperinsulinemic hypoglycemia after gastric banding. N Engl J Med 2005; 353: 28222823.
  • 165
    Catton JA, Zaitoun AM, Aithal GP, Sturrock ND, Lobo DN. Diffuse nesidioblastosis causing hyperinsulinemic hypoglycemia: the importance of pancreatic sampling on EUS. Gastrointest Endosc 2008; 68: 571572. discussion 572.
  • 166
    Wax JR, Heersink D, Pinette MG, Cartin A, Blackstone J. Symptomatic hypoglycemia complicating pregnancy following Roux-en-Y gastric bypass surgery. Obes Surg 2007; 17: 698700.
  • 167
    Zagury L, Moreira RO, Guedes EP, Coutinho WF, Appolinario JC. Insulinoma misdiagnosed as dumping syndrome after bariatric surgery. Obes Surg 2004; 14: 120123.
  • 168
    Guseva N, Phillips D, Mordes JP. Successful treatment of persistent hyperinsulinemic hypoglycemia with nifedipine in an adult patient. Endocr Pract 2010; 16: 107111.
  • 169
    Vella A, Service FJ. Incretin hypersecretion in post-gastric bypass hypoglycemia – primary problem or red herring? J Clin Endocrinol Metab 2007; 92: 45634565.
  • 170
    Bantle JP, Ikramuddin S, Kellogg TA, Buchwald H. Hyperinsulinemic hypoglycemia developing late after gastric bypass. Obes Surg 2007; 17: 592594.
  • 171
    Moreira RO, Moreira RB, Machado NA, Goncalves TB, Coutinho WF. Post-prandial hypoglycemia after bariatric surgery: pharmacological treatment with verapamil and acarbose. Obes Surg 2008; 18: 16181621.
  • 172
    McLaughlin T, Peck M, Holst J, Deacon C. Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab 2010; 95: 18511855.
  • 173
    Shah SS, Todkar JS, Shah PS, Cummings DE. Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index <35 kg/m(2). Surg Obes Relat Dis 2010 JulAug; 6(4): 332338. Epub 2009 Sep 3. PubMed PMID: 19846351; PubMed Central PMCID: PMC2888958.